Flutiform review to take longer than expected, says SkyePharma

19 October 2011

UK-based SkyePharma (LSE: SKP) revealed yesterday that the review of the European Marketing Authorization Application for Flutiform, a fixed-dose combination of fluticasone formoterol for the treatment of asthma, will take longer than originally anticipated due to lack of complete consensus by the concerned (European Union) member states (CMSs) within the timescale laid down by the decentralised review procedure.

It notes that European marketing partner privately held Swiss firm Mundipharma International has been informed that the decentralized procedure for the review of Flutiform was unable to be completed at Day 210 with a consensus of the reference member state and the 21 CMSs. The UK (the reference member state for the review of Flutiform) and almost all of the CMSs were in agreement that the product was approvable but a complete consensus was not achieved by Day 210, which was October 17, 2011.

The procedure has now moved into a referral process during which the Member States involved will use their best endeavours to achieve a consensus on the final regulatory position of Flutiform within 60 days of the process commencing. The process should normally commence within 30 days.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical